Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2
5(83.3%)
Phase 3
1(16.7%)
6Total
Phase 2(5)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06329791Phase 3Active Not Recruiting

A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Role: lead

NCT03652051Phase 2Completed

A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)

Role: lead

NCT05548491Phase 2Completed

Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Contact Lens Discomfort (CLD)

Role: lead

NCT04314362Phase 2Completed

Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)

Role: lead

NCT03972501Phase 2Completed

An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)

Role: lead

NCT04391959Phase 2Completed

Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)

Role: lead

All 6 trials loaded